Ensign Peak Advisors’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
Other funds holding HAE
VPM
VCM
RRAM
Ensign Peak Advisors's HAE Position: Q1 2026 in Review
Ensign Peak Advisors held its Haemonetics (HAE) position steady in Q1 2026 at 3,166 shares worth $178K. The position accounts for ﹤0.01% of the portfolio, ranked #1359.
Ensign Peak Advisors first reported a position in HAE in Q4 2019 and has held it in 26 quarters since. The position peaked at $6.1M in Q4 2020. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.
- Ensign Peak Advisors held 3,166 shares of Haemonetics worth $178K as of Q1 2026.
- Ensign Peak Advisors left its Haemonetics share count unchanged in Q1 2026.
- Haemonetics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q1 2026, its #1359 holding.
- Ensign Peak Advisors first reported a position in Haemonetics in Q4 2019 and has held it in 26 quarters since.
- Ensign Peak Advisors's Haemonetics position peaked at $6.1M in Q4 2020.
- 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.
Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.